Hepatitis B and C co-infection in HIV patients from the TREAT Asia HIV observational database

Analysis of risk factors and survival

Marcelo Chen, Wing Wai Wong, Matthew G. Law, Sasisopin Kiertiburanakul, Evy Yunihastuti, Tuti Parwati Merati, Poh Lian Lim, Romanee Chaiwarith, Praphan Phanuphak, Man Po Lee, Nagalingeswaran Kumarasamy, Vonthanak Saphonn, Rossana Ditangco, Benedict L.H. Sim, Kinh Van Nguyen, Sanjay Pujari, Adeeba Kamarulzaman, Fujie Zhang, Thuy Thanh Pham, JunYong Choi & 6 others Shinichi Oka, Pacharee Kantipong, Mahiran Mustafa, Winai Ratanasuwan, Nicolas Durier, Yi Ming Arthur Chen

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background We assessed the effects of hepatitis B (HBV) or hepatitis C (HCV) co-infection on outcomes of antiretroviral therapy (ART) in HIV-infected patients enrolled in the TREAT Asia HIV Observational Database (TAHOD), a multi-center cohort of HIV-infected patients in the Asia-Pacific region. Methods Patients testing HBs antigen (Ag) or HCV antibody (Ab) positive within enrollment into TAHOD were considered HBV or HCV co-infected. Factors associated with HBV and/orHCV co-infection were assessed by logistic regression models. Factors associated with post-ART HIV immunological response (CD4 change after six months) and virological response (HIV RNA <400 copies/ml after 12 months) were also determined. Survival was assessed by the Kaplan-Meier method and log rank test. Results A total of 7,455 subjects were recruited by December 2012. Of patients tested, 591/5656 (10.4%) were HBsAg positive, 794/5215 (15.2%) were HCVAb positive, and 88/4966 (1.8%) were positive for both markers. In multivariate analysis, HCV co-infection, age, route of HIV infection, baseline CD4 count, baseline HIV RNA, and HIV-1 subtype were associated with immunological recovery. Age, route of HIV infection, baseline CD4 count, baseline HIV RNA, ART regimen, prior ART and HIV-1 subtype, but not HBV or HCV co-infection, affected HIV RNA suppression. Risk factors affecting mortality included HCV co-infection, age, CDC stage, baseline CD4 count, baseline HIV RNA and prior mono/dual ART. Shortest survival was seen in subjects who were both HBV-and HCV-positive. Conclusion In this Asian cohort of HIV-infected patients, HCV co-infection, but not HBV co-infection, was associated with lower CD4 cell recovery after ART and increased mortality.

Original languageEnglish
Article numbere0150512
JournalPloS one
Volume11
Issue number3
DOIs
Publication statusPublished - 2016 Mar 1

Fingerprint

hepatitis C
hepatitis B
Survival Analysis
Hepatitis C
Hepatitis B
Coinfection
mixed infection
risk factors
HIV
Databases
RNA
therapeutics
HIV infections
Human immunodeficiency virus 1
CD4 Lymphocyte Count
Recovery
Hepatitis C Antibodies
Hepatitis B Surface Antigens
antigen detection
Logistics

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Chen, M., Wong, W. W., Law, M. G., Kiertiburanakul, S., Yunihastuti, E., Merati, T. P., ... Chen, Y. M. A. (2016). Hepatitis B and C co-infection in HIV patients from the TREAT Asia HIV observational database: Analysis of risk factors and survival. PloS one, 11(3), [e0150512]. https://doi.org/10.1371/journal.pone.0150512
Chen, Marcelo ; Wong, Wing Wai ; Law, Matthew G. ; Kiertiburanakul, Sasisopin ; Yunihastuti, Evy ; Merati, Tuti Parwati ; Lim, Poh Lian ; Chaiwarith, Romanee ; Phanuphak, Praphan ; Lee, Man Po ; Kumarasamy, Nagalingeswaran ; Saphonn, Vonthanak ; Ditangco, Rossana ; Sim, Benedict L.H. ; Van Nguyen, Kinh ; Pujari, Sanjay ; Kamarulzaman, Adeeba ; Zhang, Fujie ; Pham, Thuy Thanh ; Choi, JunYong ; Oka, Shinichi ; Kantipong, Pacharee ; Mustafa, Mahiran ; Ratanasuwan, Winai ; Durier, Nicolas ; Chen, Yi Ming Arthur. / Hepatitis B and C co-infection in HIV patients from the TREAT Asia HIV observational database : Analysis of risk factors and survival. In: PloS one. 2016 ; Vol. 11, No. 3.
@article{3c83420071104ff98610aa45b3b232ab,
title = "Hepatitis B and C co-infection in HIV patients from the TREAT Asia HIV observational database: Analysis of risk factors and survival",
abstract = "Background We assessed the effects of hepatitis B (HBV) or hepatitis C (HCV) co-infection on outcomes of antiretroviral therapy (ART) in HIV-infected patients enrolled in the TREAT Asia HIV Observational Database (TAHOD), a multi-center cohort of HIV-infected patients in the Asia-Pacific region. Methods Patients testing HBs antigen (Ag) or HCV antibody (Ab) positive within enrollment into TAHOD were considered HBV or HCV co-infected. Factors associated with HBV and/orHCV co-infection were assessed by logistic regression models. Factors associated with post-ART HIV immunological response (CD4 change after six months) and virological response (HIV RNA <400 copies/ml after 12 months) were also determined. Survival was assessed by the Kaplan-Meier method and log rank test. Results A total of 7,455 subjects were recruited by December 2012. Of patients tested, 591/5656 (10.4{\%}) were HBsAg positive, 794/5215 (15.2{\%}) were HCVAb positive, and 88/4966 (1.8{\%}) were positive for both markers. In multivariate analysis, HCV co-infection, age, route of HIV infection, baseline CD4 count, baseline HIV RNA, and HIV-1 subtype were associated with immunological recovery. Age, route of HIV infection, baseline CD4 count, baseline HIV RNA, ART regimen, prior ART and HIV-1 subtype, but not HBV or HCV co-infection, affected HIV RNA suppression. Risk factors affecting mortality included HCV co-infection, age, CDC stage, baseline CD4 count, baseline HIV RNA and prior mono/dual ART. Shortest survival was seen in subjects who were both HBV-and HCV-positive. Conclusion In this Asian cohort of HIV-infected patients, HCV co-infection, but not HBV co-infection, was associated with lower CD4 cell recovery after ART and increased mortality.",
author = "Marcelo Chen and Wong, {Wing Wai} and Law, {Matthew G.} and Sasisopin Kiertiburanakul and Evy Yunihastuti and Merati, {Tuti Parwati} and Lim, {Poh Lian} and Romanee Chaiwarith and Praphan Phanuphak and Lee, {Man Po} and Nagalingeswaran Kumarasamy and Vonthanak Saphonn and Rossana Ditangco and Sim, {Benedict L.H.} and {Van Nguyen}, Kinh and Sanjay Pujari and Adeeba Kamarulzaman and Fujie Zhang and Pham, {Thuy Thanh} and JunYong Choi and Shinichi Oka and Pacharee Kantipong and Mahiran Mustafa and Winai Ratanasuwan and Nicolas Durier and Chen, {Yi Ming Arthur}",
year = "2016",
month = "3",
day = "1",
doi = "10.1371/journal.pone.0150512",
language = "English",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "3",

}

Chen, M, Wong, WW, Law, MG, Kiertiburanakul, S, Yunihastuti, E, Merati, TP, Lim, PL, Chaiwarith, R, Phanuphak, P, Lee, MP, Kumarasamy, N, Saphonn, V, Ditangco, R, Sim, BLH, Van Nguyen, K, Pujari, S, Kamarulzaman, A, Zhang, F, Pham, TT, Choi, J, Oka, S, Kantipong, P, Mustafa, M, Ratanasuwan, W, Durier, N & Chen, YMA 2016, 'Hepatitis B and C co-infection in HIV patients from the TREAT Asia HIV observational database: Analysis of risk factors and survival', PloS one, vol. 11, no. 3, e0150512. https://doi.org/10.1371/journal.pone.0150512

Hepatitis B and C co-infection in HIV patients from the TREAT Asia HIV observational database : Analysis of risk factors and survival. / Chen, Marcelo; Wong, Wing Wai; Law, Matthew G.; Kiertiburanakul, Sasisopin; Yunihastuti, Evy; Merati, Tuti Parwati; Lim, Poh Lian; Chaiwarith, Romanee; Phanuphak, Praphan; Lee, Man Po; Kumarasamy, Nagalingeswaran; Saphonn, Vonthanak; Ditangco, Rossana; Sim, Benedict L.H.; Van Nguyen, Kinh; Pujari, Sanjay; Kamarulzaman, Adeeba; Zhang, Fujie; Pham, Thuy Thanh; Choi, JunYong; Oka, Shinichi; Kantipong, Pacharee; Mustafa, Mahiran; Ratanasuwan, Winai; Durier, Nicolas; Chen, Yi Ming Arthur.

In: PloS one, Vol. 11, No. 3, e0150512, 01.03.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hepatitis B and C co-infection in HIV patients from the TREAT Asia HIV observational database

T2 - Analysis of risk factors and survival

AU - Chen, Marcelo

AU - Wong, Wing Wai

AU - Law, Matthew G.

AU - Kiertiburanakul, Sasisopin

AU - Yunihastuti, Evy

AU - Merati, Tuti Parwati

AU - Lim, Poh Lian

AU - Chaiwarith, Romanee

AU - Phanuphak, Praphan

AU - Lee, Man Po

AU - Kumarasamy, Nagalingeswaran

AU - Saphonn, Vonthanak

AU - Ditangco, Rossana

AU - Sim, Benedict L.H.

AU - Van Nguyen, Kinh

AU - Pujari, Sanjay

AU - Kamarulzaman, Adeeba

AU - Zhang, Fujie

AU - Pham, Thuy Thanh

AU - Choi, JunYong

AU - Oka, Shinichi

AU - Kantipong, Pacharee

AU - Mustafa, Mahiran

AU - Ratanasuwan, Winai

AU - Durier, Nicolas

AU - Chen, Yi Ming Arthur

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Background We assessed the effects of hepatitis B (HBV) or hepatitis C (HCV) co-infection on outcomes of antiretroviral therapy (ART) in HIV-infected patients enrolled in the TREAT Asia HIV Observational Database (TAHOD), a multi-center cohort of HIV-infected patients in the Asia-Pacific region. Methods Patients testing HBs antigen (Ag) or HCV antibody (Ab) positive within enrollment into TAHOD were considered HBV or HCV co-infected. Factors associated with HBV and/orHCV co-infection were assessed by logistic regression models. Factors associated with post-ART HIV immunological response (CD4 change after six months) and virological response (HIV RNA <400 copies/ml after 12 months) were also determined. Survival was assessed by the Kaplan-Meier method and log rank test. Results A total of 7,455 subjects were recruited by December 2012. Of patients tested, 591/5656 (10.4%) were HBsAg positive, 794/5215 (15.2%) were HCVAb positive, and 88/4966 (1.8%) were positive for both markers. In multivariate analysis, HCV co-infection, age, route of HIV infection, baseline CD4 count, baseline HIV RNA, and HIV-1 subtype were associated with immunological recovery. Age, route of HIV infection, baseline CD4 count, baseline HIV RNA, ART regimen, prior ART and HIV-1 subtype, but not HBV or HCV co-infection, affected HIV RNA suppression. Risk factors affecting mortality included HCV co-infection, age, CDC stage, baseline CD4 count, baseline HIV RNA and prior mono/dual ART. Shortest survival was seen in subjects who were both HBV-and HCV-positive. Conclusion In this Asian cohort of HIV-infected patients, HCV co-infection, but not HBV co-infection, was associated with lower CD4 cell recovery after ART and increased mortality.

AB - Background We assessed the effects of hepatitis B (HBV) or hepatitis C (HCV) co-infection on outcomes of antiretroviral therapy (ART) in HIV-infected patients enrolled in the TREAT Asia HIV Observational Database (TAHOD), a multi-center cohort of HIV-infected patients in the Asia-Pacific region. Methods Patients testing HBs antigen (Ag) or HCV antibody (Ab) positive within enrollment into TAHOD were considered HBV or HCV co-infected. Factors associated with HBV and/orHCV co-infection were assessed by logistic regression models. Factors associated with post-ART HIV immunological response (CD4 change after six months) and virological response (HIV RNA <400 copies/ml after 12 months) were also determined. Survival was assessed by the Kaplan-Meier method and log rank test. Results A total of 7,455 subjects were recruited by December 2012. Of patients tested, 591/5656 (10.4%) were HBsAg positive, 794/5215 (15.2%) were HCVAb positive, and 88/4966 (1.8%) were positive for both markers. In multivariate analysis, HCV co-infection, age, route of HIV infection, baseline CD4 count, baseline HIV RNA, and HIV-1 subtype were associated with immunological recovery. Age, route of HIV infection, baseline CD4 count, baseline HIV RNA, ART regimen, prior ART and HIV-1 subtype, but not HBV or HCV co-infection, affected HIV RNA suppression. Risk factors affecting mortality included HCV co-infection, age, CDC stage, baseline CD4 count, baseline HIV RNA and prior mono/dual ART. Shortest survival was seen in subjects who were both HBV-and HCV-positive. Conclusion In this Asian cohort of HIV-infected patients, HCV co-infection, but not HBV co-infection, was associated with lower CD4 cell recovery after ART and increased mortality.

UR - http://www.scopus.com/inward/record.url?scp=84961116142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961116142&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0150512

DO - 10.1371/journal.pone.0150512

M3 - Article

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 3

M1 - e0150512

ER -